Oncology Venture APS
http://oncologyventure.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oncology Venture APS
Pipeline Watch: Phase III Trials Initiated For AMT-061, RP-G28 And APL-2
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Starts For Molidustat, Tecentriq And Tislelizumab
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Deal Watch: Gilead And Spring Bank Set Second Trial Collaboration In HBV
Analyst speculates that Gilead could move to acquire Spring Bank if combo trial yields promising data for functional cure of hepatitis B. Eisai in-licenses PARP inhibitor with potential in breast cancer from Oncology Venture, while Sunovion out-licenses three corticosteroid products to Covis.
Deals Shaping The Medical Industry, December 2012
Derived from Strategic Transactions, EBI’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals– and then categorized by type –Acquisition, Alliance, or Financing.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice